scPharmaceuticals (NASDAQ:SCPH) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a $18.00 price target on the stock.

scPharmaceuticals Trading Down 0.3 %

NASDAQ:SCPH opened at $3.00 on Thursday. scPharmaceuticals has a 52 week low of $2.75 and a 52 week high of $5.65. The firm has a 50 day moving average of $3.27 and a 200 day moving average of $3.78. The company has a quick ratio of 6.89, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $150.12 million, a price-to-earnings ratio of -1.58 and a beta of 0.40.

scPharmaceuticals (NASDAQ:SCPH) last posted its earnings results on Wednesday, March 19th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.05. scPharmaceuticals had a negative net margin of 264.60% and a negative return on equity of 244.93%. The company had revenue of $12.15 million during the quarter, compared to analysts’ expectations of $12.08 million. As a group, sell-side analysts anticipate that scPharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SCPH. Suvretta Capital Management LLC purchased a new position in shares of scPharmaceuticals in the third quarter worth $9,343,000. Rubric Capital Management LP raised its holdings in shares of scPharmaceuticals by 35.5% in the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after buying an additional 1,250,000 shares during the last quarter. King Luther Capital Management Corp raised its holdings in shares of scPharmaceuticals by 28.4% in the fourth quarter. King Luther Capital Management Corp now owns 2,857,910 shares of the company’s stock worth $10,117,000 after buying an additional 632,120 shares during the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of scPharmaceuticals by 59.2% in the fourth quarter. Rice Hall James & Associates LLC now owns 989,635 shares of the company’s stock worth $3,503,000 after buying an additional 367,970 shares during the last quarter. Finally, Stonepine Capital Management LLC raised its holdings in shares of scPharmaceuticals by 84.7% in the third quarter. Stonepine Capital Management LLC now owns 778,874 shares of the company’s stock worth $3,552,000 after buying an additional 357,171 shares during the last quarter. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.